Cargando…
After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine?
In 2021, most of the world was reasonably still concerned about the COVID-19 pandemic, how cases were up and down in different countries, how the vaccination campaigns were ongoing, and most people were familiar with the speed with which vaccines against SARS-Co-V2 were developed, analyzed, and star...
Autor principal: | Flores-Valdez, Mario Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778337/ https://www.ncbi.nlm.nih.gov/pubmed/35062718 http://dx.doi.org/10.3390/vaccines10010057 |
Ejemplares similares
-
Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c
por: Gunasena, Manuja, et al.
Publicado: (2022) -
100 Years of BCG Immunization: Past, Present, and Future
por: Tagliabue, Aldo, et al.
Publicado: (2022) -
Vaccination with BCGΔBCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG
por: Aceves-Sánchez, Michel de Jesús, et al.
Publicado: (2021) -
Genome sequences of BCG Pasteur ATCC 35734 and its derivative, the vaccine candidate BCGΔBCG1419c
por: D’Auria, Giuseppe, et al.
Publicado: (2023) -
BCG Vaccination Prevents Reactivation of Latent Lymphatic Murine Tuberculosis Independently of CD4(+) T Cells
por: Sathkumara, Harindra D., et al.
Publicado: (2019)